342 related articles for article (PubMed ID: 20810155)
21. IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series.
Carruthers MN; Park S; Slack GW; Dalal BI; Skinnider BF; Schaeffer DF; Dutz JP; Law JK; Donnellan F; Marquez V; Seidman M; Wong PC; Mattman A; Chen LY
Eur J Haematol; 2017 Apr; 98(4):378-387. PubMed ID: 28005278
[TBL] [Abstract][Full Text] [Related]
22. Marked and persistent eosinophilia in the absence of clinical manifestations.
Chen YY; Khoury P; Ware JM; Holland-Thomas NC; Stoddard JL; Gurprasad S; Waldner AJ; Klion AD
J Allergy Clin Immunol; 2014 Apr; 133(4):1195-202. PubMed ID: 23987798
[TBL] [Abstract][Full Text] [Related]
23. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
Helbig G; Kyrcz-Krzemień S
Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions.
Büttner C; Lun A; Splettstoesser T; Kunkel G; Renz H
Eur Respir J; 2003 May; 21(5):799-803. PubMed ID: 12765424
[TBL] [Abstract][Full Text] [Related]
26. What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review.
Shi Y; Wang C
Clin Immunol; 2022 Apr; 237():108982. PubMed ID: 35307610
[TBL] [Abstract][Full Text] [Related]
27. The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES).
Helbig G; Wichary R; Razny M; Rodzaj M; Wozniczka K; Dziaczkowska-Suszek J; Kyrcz-Krzemien S
Scand J Immunol; 2010 Oct; 72(4):372-3. PubMed ID: 20883323
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
Smith DA; Minthorn EA; Beerahee M
Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
[TBL] [Abstract][Full Text] [Related]
29. Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
Pane F; Lefevre G; Kwon N; Bentley JH; Yancey SW; Steinfeld J
Front Immunol; 2022; 13():935996. PubMed ID: 36091012
[TBL] [Abstract][Full Text] [Related]
30. Hypereosinophilic syndromes.
Roufosse FE; Goldman M; Cogan E
Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.
Schrezenmeier H; Thomé SD; Tewald F; Fleischer B; Raghavachar A
Exp Hematol; 1993 Feb; 21(2):358-65. PubMed ID: 8425573
[TBL] [Abstract][Full Text] [Related]
32. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
33. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
34. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.
Lefèvre G; Copin MC; Roumier C; Aubert H; Avenel-Audran M; Grardel N; Poulain S; Staumont-Sallé D; Seneschal J; Salles G; Ghomari K; Terriou L; Leclech C; Morati-Hafsaoui C; Morschhauser F; Lambotte O; Ackerman F; Trauet J; Geffroy S; Dumezy F; Capron M; Roche-Lestienne C; Taieb A; Hatron PY; Dubucquoi S; Hachulla E; Prin L; Labalette M; Launay D; Preudhomme C; Kahn JE;
Haematologica; 2015 Aug; 100(8):1086-95. PubMed ID: 25682606
[TBL] [Abstract][Full Text] [Related]
35. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.
Helbig G; Wieczorkiewicz A; Dziaczkowska-Suszek J; Majewski M; Kyrcz-Krzemien S
Haematologica; 2009 Sep; 94(9):1236-41. PubMed ID: 19734416
[TBL] [Abstract][Full Text] [Related]
36. New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states.
Berki T; Dávid M; Bóné B; Losonczy H; Vass J; Németh P
Pathol Oncol Res; 2001; 7(4):292-7. PubMed ID: 11882909
[TBL] [Abstract][Full Text] [Related]
37. Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome.
Tabata R; Tabata C; Katashima Y; Yasumizu R
Int Immunopharmacol; 2013 Aug; 16(4):488-91. PubMed ID: 23669338
[TBL] [Abstract][Full Text] [Related]
38. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
[TBL] [Abstract][Full Text] [Related]
39. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA
Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325
[TBL] [Abstract][Full Text] [Related]
40. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
